通过调节ALKBH5在肺癌中的翻译后修饰,KRAS突变赋予抗性
Fang Yu1,2, Shikan Zheng3, Chunjie Yu1,2
1Department of Medicine, University of Florida Health Cancer Center and.
The Journal of clinical investigation
|February 17, 2025
概括
非小细胞肺癌 (NSCLC) 中的KRAS突变通过通过m6A甲基化增加DNA修复来驱动白金化疗耐药性. 抑制这种途径使耐药物NSCLC细胞敏感.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 构成性活跃的KRAS突变在非小细胞肺癌 (NSCLC) 中很常见.
- 将KRAS突变与化疗耐药性联系在一起的机制尚未完全理解.
- 了解这些机制对于开发有效的NSCLC治疗至关重要.
研究的目的:
- 研究KRAS突变如何在NSCLC中对基化疗产生抗性.
- 阐明KRAS介导的抗性背后的分子机制.
- 确定潜在的治疗点,以克服KRAS突变NSCLC中的化疗抵抗.
主要方法:
- 研究了KRAS突变在NSCLC细胞系中抗性的作用.
- 分析了ERK/JNK信号传递和AlkB同源5 (ALKBH5) 后翻译修饰 (PTM) 的参与.
- 评估了m6A甲基化对DNA修复基因 (DDB2,XPC) 和核酸切割修复的影响.
- 在体外和体内评估抑制m6A甲基化 (ALKBH5突变,METTL3抑制) 的疗效.
主要成果:
- 克拉斯突变激活ERK/JNK信号,通过PTMs抑制ALKBH5脱甲基酶的活性.
- 这导致DDB2和XPCmRNA的m6A甲基化增加,增强DNA修复和促进抗性.
- 过度表达SUMOylation缺陷的ALKBH5突变体或抑制METTL3使KRAS突变NSCLC细胞对药物敏感.
- 这些发现在体外和体外模型中得到了验证.
结论:
- 克拉斯突变通过激活通过ERK/JNK/ALKBH5/m6A轴的DNA修复途径来调解NSCLC中的抗性.
- 向m6A甲基化是一种有前途的策略,可以克服KRAS突变NSCLC中的化学抵抗.
- 这项研究揭示了一种新的化学抵抗机制,以及NSCLC的潜在治疗脆弱性.
相关概念视频
The Ras Gene
6.1K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.1K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Covalently Linked Protein Regulators
6.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.8K


